Alembic Pharmaceuticals Receives USFDA Approval for Paroxetine ER Tablets

Alembic Pharmaceuticals announced it has received final approval from the U.S. Food & Drug Administration (USFDA) for its Paroxetine Extended-Release Tablets USP, 12.5 mg. This approval was granted through a supplemental Abbreviated New Drug Application (sANDA).

The newly approved generic drug is considered therapeutically equivalent to Apotex Inc.'s Paxil CR Tablets. It is indicated for treating major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder.

This latest approval brings Alembic's total cumulative Abbreviated New Drug Application (ANDA) count to 235, which includes 216 final approvals and 19 tentative approvals.

This USFDA clearance is a significant validation for Alembic Pharmaceuticals, reinforcing its capabilities in developing and obtaining regulatory approval for generic formulations in the key U.S. market. The expansion of its product offerings strengthens its revenue streams and market position in the U.S. generics sector.

Alembic has a consistent focus on growing its U.S. FDA approval pipeline and a strong history of securing both tentative and final approvals. For shareholders, this means a more robust product offering within Alembic's U.S. generics portfolio, with potential for increased revenue generation from the new Paroxetine ER Tablets and further diversification of its therapeutic offerings in the U.S.

However, the U.S. generic pharmaceutical market remains highly competitive. Alembic will likely face ongoing pricing pressures and intense competition from both established manufacturers and new market entrants.

Other major Indian pharmaceutical companies like Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Cipla Ltd. also maintain significant U.S. generics businesses, often announcing similar approvals that contribute to their growth.

As of March 27, 2026, Alembic Pharmaceuticals has achieved 216 final and 19 tentative ANDA approvals from the USFDA. Investors and observers will be tracking the successful commercial launch and market uptake of the Paroxetine ER Tablets, along with future approvals from Alembic's pipeline and the performance of its U.S. generics segment against competitors.